Holen Sie sich die Stockscreener-App
84.61
1.09%
0.91
Handel nachbörslich:
84.61
Schlusskurs vom Vortag:
$83.70
Offen:
$83.85
24-Stunden-Volumen:
1.34M
Relative Volume:
0.73
Marktkapitalisierung:
$16.52B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
19.23
EPS:
4.4
Netto-Cashflow:
$945.58M
1W Leistung:
-0.51%
1M Leistung:
+9.35%
6M Leistung:
+15.62%
1J Leistung:
+28.37%
1-Tages-Spanne:
$83.41
$84.63
1-Wochen-Bereich:
$83.41
$85.87
52-Wochen-Spanne:
$53.56
$87.24
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
84.61 | 16.34B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Reversal indicators forming on Incyte Corporation stockEarnings Recap Summary & Short-Term High Return Strategies - Newser
What candlestick patterns are forming on Incyte CorporationJuly 2025 Pullbacks & Expert Verified Movement Alerts - Newser
Long term hold vs stop loss in Incyte CorporationJuly 2025 Catalysts & Verified Momentum Stock Ideas - Newser
Should you wait for a breakout in Incyte Corporation2025 Geopolitical Influence & High Accuracy Investment Signals - Newser
Can technical indicators confirm Incyte Corporation’s reversalBull Run & Expert-Curated Trade Recommendations - Newser
Applying Elliott Wave Theory to Incyte CorporationJuly 2025 Market Mood & Low Risk High Reward Trade Ideas - Newser
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype? - sharewise.com
Quantitative breakdown of Incyte Corporation recent moveWeekly Earnings Recap & Fast Entry Momentum Alerts - Newser
What indicators show strength in Incyte CorporationGap Up & Free Technical Confirmation Trade Alerts - Newser
Will Incyte Corporation stock recover after recent dropMarket Growth Report & Fast Gain Stock Tips - Newser
Detecting support and resistance levels for Incyte CorporationJuly 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
What Fibonacci levels say about Incyte Corporation reboundPortfolio Performance Summary & High Accuracy Buy Signal Tips - Newser
How sentiment analysis helps forecast Incyte Corporation2025 Price Momentum & Short-Term Swing Trade Alerts - Newser
Is Incyte Corporation likely to announce a buybackMarket Growth Report & AI Driven Stock Price Forecasts - sundaytimes.kr
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? - MSN
Published on: 2025-08-28 10:23:57 - Newser
Evaluating Incyte Corporation with trendline analysis2025 Institutional Moves & Weekly Market Pulse Updates - Newser
Will breakout in Incyte Corporation lead to full recoveryDollar Strength & Capital Efficiency Focused Ideas - Newser
What’s the recovery path for long term holders of Incyte CorporationJuly 2025 Decliners & Breakout Confirmation Alerts - Newser
Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership - Insider Monkey
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 27, 2025 - BioSpace
Chart based analysis of Incyte Corporation trends2025 Stock Rankings & Growth Oriented Trading Recommendations - Newser
Incyte reports inducement grant under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Using RSI to spot recovery in Incyte CorporationMarket Trend Summary & Growth Focused Entry Reports - Newser
What institutional flow reveals about Incyte CorporationBull Run & Safe Capital Growth Plans - Newser
Three Biotech Companies to Watch: Boston Scientific, Arcutis Biotherapeutics, and Incyte Corporation - AInvest
How institutional ownership impacts Incyte Corporation stockJuly 2025 Highlights & Safe Swing Trade Setup Alerts - Newser
Will Incyte Corporation rebound enough to break evenJuly 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):